Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-11.8%
· vs SPY
-13.9%
· Prev Value $881.29M
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
+13.7%
· vs SPY
+11.5%
· Latest Value $631.19M
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Atlas Venture Life Science Advisors, LLC disclosed 9 equity positions with a combined reported value of $631.19M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were KYMR ($318.33M), IRON ($90.60M), VRDN ($61.83M). By sector, the heaviest allocations are Health Care 100.0%.
Versus the prior quarter, Atlas Venture Life Science Advisors, LLC opened 2 new positions, trimmed 3 and fully exited 0, a turnover rate of 55.6% of positions. The portfolio's overlap with the prior quarter was 78% of names.
The largest new positions opened in Q3 2026 were VRDN ($61.83M), ODTX ($59.82K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Atlas Venture Life Science Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Atlas Venture Life Science Advisors, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $881.29M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
7 positions · $881.29M reported value (Q2 2026)
Top 10 holdings = 100.0% of reported value
Largest position: KYMR (KYMERA THERAPEUTICS INC) at 37.1%
Average position size: $125.90M
Sector Tilt
Health Care 100.0%
(classified holdings cover 100% of value)
Quarterly Activity
Q2 2026: 1 new, 1 added, 3 reduced
2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund increased concentration in top holdings (KYMR surged to 50.43% weight), reduced exposure to several biotech names (DYN, IRON, KRRO, SION), and added two new positions (VRDN, ODTX), suggesting a bullish tilt toward core holdings while trimming secondary bets.
2. Key moves:
- Reduced: DYN (-49.4% shares), IRON (-8.6% shares), KRRO (-19.7% shares), SION (-12.45% weight, though shares unchanged).
- Added: VRDN (new, 9.80% weight), ODTX (new, 0.01% weight).
3. Portfolio structure: Active, high-conviction (top 3 holdings = 74.58% weight), heavily Health Care-focused (100%), with moderate risk appetite (concentration in volatile biotechs).
4. Per-holding one-liner:
- KYMR: Kymera Therapeutics (biopharma, unverified).
- IRON: Disc Medicine (hematology-focused biotech, unverified).
- VRDN: Viridian Therapeutics (thyroid disease biotech, unverified).
- KLRA: Kailera Therapeutics (immunology biotech, unverified).
- DYN: Dyne Therapeutics (muscular dystrophy biotech, unverified).
- QTTB: Q32 Bio (oncology biotech, unverified).
- SION: Sionna Therapeutics (genetic medicine biotech, unverified).
- KRRO: Korro Bio (gene editing biotech, unverified).
- ODTX: Odyssey Therapeutics (AI-driven drug discovery, unverified).
5. Style summary: High-conviction biotech fund doubling down on winners while pruning losers, with cautious new bets.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-14 05:53
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2025-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
Why there is no forecast NAV
Not published because:
no_curve
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-12.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-12, and will update as prices arrive.
Portfolio return-5.54%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+5.61%vs benchmark
Barra annualised vol84.5%Model estimate
Realised vol75.7%Annualised in window
Weighted beta1.49Raw exposure
Factor / specific risk32% / 68%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-5.54%
Disclosed long book
QQQ synthetic benchmark
-11.15%
Liquidity-weighted constituents
Model universe, equal weight
+2.04%
Opportunity-cost reference
Excess return
+5.61%
Portfolio − benchmark
Arithmetic return sum
-2.18%
Difference vs compounded is the cross term
Weighted raw beta
1.49
Weighted holding betas
Realised volatility (annualised)
75.67%
Daily returns in window
Barra model volatility (annualised)
84.50%
Factor + specific
Factor share of variance
31.8%
Barra factors
Specific share of variance
68.2%
Stock residuals
Reported value
$59,816
13F long US equity
2. Return attribution
The -2.18% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-1.08%
-49.5%
Momentum & Growth
3
-0.09%
-4.0%
Volatility & Tail Risk
7
-19.51%
-896.5%
Industry
12
+9.47%
435.1%
Specific
1
+9.03%
414.9%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Health Care
Industry
+1.00
+9.47%
+9.47%
435.1%
Specific
Specific
—
—
+9.03%
414.9%
Size
Style
-1.66
-1.93%
+3.20%
146.9%
Beta
Style
+0.65
+4.92%
+3.18%
146.3%
Residual Volatility
Style
+1.36
+2.15%
+2.92%
134.3%
Skewness
Style
-0.34
-4.77%
+1.62%
74.3%
Short-term Reversal
Style
+0.84
+1.12%
+0.94%
43.0%
Amihud Illiquidity
Style
+2.75
+0.30%
+0.83%
38.0%
Growth
Style
+0.16
+1.50%
+0.24%
11.0%
Non-linear Size
Style
+3.07
+0.07%
+0.21%
9.7%
Liquidity
Style
+1.04
-0.20%
-0.21%
-9.8%
Max Drawdown
Style
+0.98
-1.01%
-0.99%
-45.7%
Momentum
Style
+0.38
-3.32%
-1.26%
-58.0%
Leverage (Downside Vol)
Style
+0.92
-3.05%
-2.80%
-128.9%
Kurtosis
Style
-0.68
+6.17%
-4.23%
-194.3%
Mid Cap
Style
+2.67
-1.92%
-5.12%
-235.4%
Historical Volatility
Style
+1.96
-9.82%
-19.20%
-882.5%
3. Risk attribution
Annualised volatility is 84.50%; factor risk explains 31.8% of variance and specific risk 68.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
68.2%
+57.59%
57.6%
Historical Volatility
Style
+1.96
9.6%
+8.09%
8.1%
Mid Cap
Style
+2.67
3.9%
+3.31%
3.3%
Health Care
Industry
+1.00
3.8%
+3.18%
3.2%
Max Drawdown
Style
+0.98
2.5%
+2.12%
2.1%
Residual Volatility
Style
+1.36
2.4%
+1.99%
2.0%
Non-linear Size
Style
+3.07
2.2%
+1.86%
1.9%
Beta
Style
+0.65
2.1%
+1.80%
1.8%
Leverage (Downside Vol)
Style
+0.92
1.5%
+1.27%
1.3%
Short-term Reversal
Style
+0.84
1.1%
+0.96%
1.0%
Kurtosis
Style
-0.68
1.1%
+0.89%
0.9%
Size
Style
-1.66
1.0%
+0.84%
0.8%
Liquidity
Style
+1.04
0.7%
+0.61%
0.6%
Growth
Style
+0.16
0.4%
+0.30%
0.3%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.66
+2.10
-3.76
Non-linear Size
+3.07
+1.68
+1.39
Mid Cap
+2.67
+0.13
+2.54
Beta
+0.65
+1.29
-0.65
Momentum
+0.38
+0.72
-0.34
Short-term Reversal
+0.84
-0.64
+1.48
Residual Volatility
+1.36
-0.40
+1.76
Historical Volatility
+1.96
+0.86
+1.10
Liquidity
+1.04
+0.11
+0.93
Amihud Illiquidity
+2.75
+1.16
+1.60
Turnover
-0.01
+0.21
-0.21
Growth
+0.16
+0.58
-0.42
Leverage (Downside Vol)
+0.92
+0.14
+0.78
Skewness
-0.34
+0.24
-0.58
Kurtosis
-0.69
+0.21
-0.90
Max Drawdown
+0.98
-0.08
+1.06
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-16.67%
+4.61%
+12.27%
-12.27%
+12.27%
Communication Services
0.0%
2.6%
+0.00%
-12.15%
+0.05%
+0.32%
-0.32%
+0.32%
Utilities
0.0%
0.8%
+0.00%
+10.14%
-0.16%
-0.08%
+0.08%
-0.08%
Consumer Staples
0.0%
0.8%
+0.00%
+15.33%
-0.22%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+5.93%
-1.44%
-0.52%
+0.52%
-0.52%
Industrials
0.0%
11.1%
+0.00%
+7.87%
-2.03%
-0.87%
+0.87%
-0.87%
Health Care
100.0%
1.7%
-5.54%
+9.50%
+19.56%
-0.26%
-14.77%
-5.70%
Total
+20.28%
+10.69%
-25.72%
+5.25%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
ODTX
Odyssey Therapeutics Inc
Health Care
100.00%
-5.54%
-5.54%
New
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
ODTX
Health Care
100.00%
-5.54%
-5.54%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-12 (31 trading days), the reported portfolio returned -5.54%, versus -11.15% for the QQQ synthetic benchmark — an excess of +5.61%.
Return attribution: the largest positive style/industry contributions came from Health Care +9.47%, Size +3.20%, Beta +3.18%; the largest drags came from Historical Volatility -19.20%, Mid Cap -5.12%, Kurtosis -4.23%. Specific (stock-level) return contributed +9.03%.
Risk attribution: Barra model volatility is 84.50% annualised; factor risk explains 32% of variance and specific risk 68%. The largest factor risk sources are Historical Volatility 9.6%, Mid Cap 3.9%, Health Care 3.8%.
Style tilt: size -1.66, momentum +0.38, volatility +1.96, liquidity +1.04; the weighted raw beta is 1.49. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.28%, selection +10.69% and interaction -25.72%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Atlas Venture Life Science Advisors, LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, Atlas Venture Life Science Advisors, LLC reported 9 equity positions worth $631.19M in aggregate; its largest disclosed positions were KYMR ($318.33M), IRON ($90.60M), VRDN ($61.83M).
How large is Atlas Venture Life Science Advisors, LLC's portfolio?
Atlas Venture Life Science Advisors, LLC reported $631.19M of long equity holdings across 9 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.
What is Atlas Venture Life Science Advisors, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/atlas-venture-life-science-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>